Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis

Treatment of patients with the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) with mepolizumab, a monoclonal antibody to interleukin-5 (IL-5) that reduces blood eosinophil counts, as an add-on therapy to glucocorticoid treatment, results in more accrued weeks in remission, reducti...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatol Int
Main Authors: Condreay, Lynn D., Parham, Laura R., Qu, Xiaoyan A., Steinfeld, Jonathan, Wechsler, Michael E., Raby, Benjamin A., Yancey, Steven W., Ghosh, Soumitra
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2020
Subjects:
Genes and Disease
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7316687/
https://ncbi.nlm.nih.gov/pubmed/32009195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-020-04523-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items